• 1. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 2. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 3. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 4. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 5. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696

Trandolaprilat Methyl Ester (CAS No. 118194-41-5): An Overview of Its Properties and Applications

Trandolaprilat Methyl Ester (CAS No. 118194-41-5) is a significant compound in the field of medicinal chemistry, particularly in the development of antihypertensive drugs. This compound is a methyl ester derivative of trandolaprilat, which is an active metabolite of trandolapril, a widely used angiotensin-converting enzyme (ACE) inhibitor. The structural modification from trandolapril to trandolaprilat methyl ester enhances its pharmacological properties, making it a valuable intermediate in pharmaceutical research and development.

The chemical structure of trandolaprilat methyl ester is characterized by a complex arrangement of functional groups, including an ester, a carboxylic acid, and a tetrazole ring. These functional groups contribute to its unique pharmacological profile, enabling it to effectively inhibit the ACE enzyme and thereby reduce blood pressure. The tetrazole ring, in particular, is known for its high affinity for the ACE enzyme, which is crucial for its therapeutic efficacy.

In recent years, significant advancements have been made in understanding the mechanisms of action and potential applications of trandolaprilat methyl ester. Research has shown that this compound not only exhibits potent ACE-inhibitory activity but also demonstrates additional beneficial effects such as antioxidant and anti-inflammatory properties. These properties make it a promising candidate for the treatment of various cardiovascular diseases beyond hypertension.

Clinical trials have further validated the safety and efficacy of trandolaprilat methyl ester. Studies have demonstrated that it effectively lowers blood pressure without causing significant side effects, making it a favorable option for long-term use in hypertensive patients. Additionally, its ability to improve endothelial function and reduce oxidative stress has been highlighted in several preclinical studies, suggesting potential benefits in preventing cardiovascular complications.

The synthesis of trandolaprilat methyl ester involves several steps, including the conversion of trandolapril to trandolaprilat through enzymatic hydrolysis and subsequent esterification with methanol. This process requires precise control over reaction conditions to ensure high yield and purity. Recent advancements in synthetic methodologies have led to more efficient and environmentally friendly processes, which are crucial for large-scale production in the pharmaceutical industry.

In terms of pharmacokinetics, trandolaprilat methyl ester exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties. It is rapidly absorbed after oral administration and undergoes extensive first-pass metabolism to form trandolaprilat, which is then distributed throughout the body. The half-life of trandolaprilat is relatively long, allowing for once-daily dosing regimens. This characteristic enhances patient compliance and convenience.

The therapeutic potential of trandolaprilat methyl ester extends beyond its primary use as an antihypertensive agent. Emerging research suggests that it may also have protective effects against renal damage in patients with diabetic nephropathy. Studies have shown that it can reduce proteinuria and improve renal function by inhibiting the renin-angiotensin system (RAS) and reducing oxidative stress in renal tissues.

In conclusion, trandolaprilat methyl ester (CAS No. 118194-41-5) is a versatile compound with significant potential in the treatment of hypertension and related cardiovascular diseases. Its unique chemical structure and pharmacological properties make it a valuable asset in pharmaceutical research and development. Ongoing research continues to uncover new applications and mechanisms of action, further solidifying its importance in the field of medicinal chemistry.

• 76420-72-9((2S)-1-(2S)-2-{(1S)-1-carboxy-3-phenylpropylamino}propanoylpyrrolidine-2-carboxylic acid)
• 75847-73-3(Enalapril)
• 87333-19-5(Ramipril)
• 87679-37-6(Trandolapril)
• 87679-71-8(Trandolaprilat)
• 108731-95-9(Ramipril diketopiperazine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)